Patent or not, that is the question
November 16. 2023
Does it really take a patent and billions of kroner for the media to take an interest in even sensationally good results?
The other day, an article (1) appeared in the newspaper *Politiken* about Ozempic and Wegovy (semaglutide), featuring an interview with Professor Jens Søndergaard. He stated that a recent study from the Cleveland Clinic had shown a 20% reduction in serious cardiovascular events after four years of treatment—a medical breakthrough so significant that he had never seen anything like it, comparing it to the discovery of penicillin. It is a major development.
Semaglutide costs DKK 2,400 per month and has side effects such as an upset stomach and nausea.
The result is quite impressive, even though it represents a relative risk reduction. However, other scientific studies from this year have shown far more impressive results.
What if there were a treatment that, after four years, demonstrated a reduction in cardiovascular mortality of over 50%—at a cost of DKK 369 per month and with absolutely no side effects? … Say what?
Yes, that is precisely the conclusion of the 10-year follow-up to the 2013 study (2) on the combination of selenium and CoQ10.
The study (3) was previously described in the Vitality Council newsletter dated April 23, 2023, and that is not what I intend to focus on here. Rather, I want to address the way news is selected by the media.
It strikes me as truly remarkable that a 20% risk reduction for cardiac events generates massive headlines and unreserved admiration, whereas an equally valid study—which actually shows a reduction in cardiovascular mortality of over 50%—is not even mentioned in those same newspapers. And it is worth noting that there is absolutely no fault to be found with the quality of this study.
Is it because it seems too good to be true that people won’t even bother reading the scientific article, or must a treatment necessarily be an expensive prescription drug with side effects to be of interest?
Professor Urban Alehagen actually doubted his own results at first; he analyzed them repeatedly from various angles but arrived at the same conclusion.
And he is certainly not alone; numerous previous studies have consistently shown increased survival rates associated with selenium and/or Q10.
Senior Consultant Sven Aage Mortensen at Rigshospitalet published several excellent studies (4) on Q10 for heart failure, yet they failed to gain any traction within the highly orthodox medical community.
After all, substances like Q10 cannot be patented. Is that where the problem lies? A patent opens the door to exorbitant profits—and the resulting marketing, press coverage, and so on—as well as funding for further research, publications, and media outreach. It creates a self-reinforcing cycle that simply spins faster and faster.
Substances that cannot be patented easily get lost in the media noise because there is little interest when there isn’t big money involved. Yet, precisely for that reason, we ought to take an even greater interest in the serious research being conducted on these products; Alehagen’s studies have clearly demonstrated that an expensive, patented product is not required to cut the risk of dying from cardiovascular disease in half.
It is simply incredible that this story has not made the front pages of the media.
Take care of yourself and others.
Claus Hancke
Specialist in general medicine
- Politiken 13/11-2023
- U Alehagen et al. Int J Cardiol 2013;167:1860-1866.
- U Alehagen et al. Antioxidants 2023, 12, 759
- https://iubmb.onlinelibrary.wiley.com/doi/abs/10.1002/biof.5520180210
